partnership with the Assistance Publique - Hôpitaux de Paris (APHP)

Français English Chinois
News
Visit our new website dedicated to services

Excilone
6-10 Rue Blaise Pascal
78990 Elancourt France


All rights reserved © 2019



News

partnership with the Assistance Publique - Hôpitaux de Paris (APHP)

 

  

                       

 

 

The French company Excilone continues its successful growth and announces the effective signature on the August 27th 2015 of two contracts of partnership framing services and research activities with the Assistance Publique - Hôpitaux de Paris (APHP).

Based at Elancourt in Yvelines (Paris region), Excilone is specialized in Digital Pathology and in Micro-NanoGenomics.

This partnership has been signed with the Professor Philippe MANIVET from the Biological Resources Centre (Biobank CRB-LRB, BB-0033-00064) of the Saint Louis-Lariboisière-Fernand Widal hospital group, based at the LariboisièreHospital in Paris.

The first aspect of this partnership concerns services offered to third parties by using the DEPArray® technology. The Excilone Company will install this patented technology within the highly specialized analytical platform of the CRB at the Lariboisière hospital for isolating rare and unique cells and other rare elements from various biological fluids. This unique service activity will be addressed both to private laboratories (CRO, pharmaceutical industry) as well as public institutions (research academic labs, Inserm, CNRS, etc) and will allow the scientific community the access to an innovative technology. The main goal of this activity will be either to allow a better understanding of specific cell mechanisms, or to detect cellular anomalies at an early stage, long before being detected by conventional techniques (medical imaging, conventional biochemistry), and prior the symptomatic expression of the pathology.

The second aspect of this partnership is dedicated to a joint project focused on the development of innovative tools urgently needed for the human diseases diagnostic made from the identification, isolation and study in biological samples (biological fluids, biopsies, cancer cell lines, iPS, etc) of rare cells (circulating tumor cells (CTC), circulating endothelial cells (CEC), fetal cells, stem cells, micro dissected cells, etc).

This research project should lead to the validation of new tools allowing the fine tuned non invasive analysis of human samples, at an early stage of the disease development, to better understand its pathophysiological mechanisms, and for the discovery of early diagnostic, prognostic biomarkers or for the follow-up of the treatments efficacy.